Literature DB >> 29709092

The vaginal microbiome amplifies sex hormone-associated cyclic changes in cervicovaginal inflammation and epithelial barrier disruption.

Frideborg Bradley1, Kenzie Birse2,3, Klara Hasselrot1,4, Laura Noël-Romas2,3, Andrea Introini1, Hugo Wefer5,6, Maike Seifert5,6, Lars Engstrand5,6, Annelie Tjernlund1, Kristina Broliden1, Adam D Burgener1,2,3.   

Abstract

PROBLEM: Susceptibility to HIV is associated with the menstrual cycle and vaginal microbiome, but their collective impact on vaginal inflammation remains unclear. Here, we characterized the cervicovaginal proteome, inflammation, and microbiome community structure and function during the menstrual cycle. METHOD OF STUDY: Cervicovaginal secretions were collected from regularly cycling women (n = 16) at median day 10, 16, and 24 of each menstrual cycle and analyzed by mass spectrometry, 16S rRNA gene sequencing, and a multiplex bead array immunoassay. Follicular, ovulatory, and luteal phases were defined by serum sex hormone levels.
RESULTS: Ovulation showed the largest mucosal proteome changes, where 30% and 19% of the 406 human proteins identified differed compared to the luteal and follicular phases, respectively. Neutrophil/leukocyte migration pathways were lowest during ovulation and peaked in the luteal phase, while antimicrobial and epithelial barrier promoting proteins were highest during ovulation. Vaginal microbial community structure and function did not vary significantly during the menstrual cycle, with the majority consistently Lactobacillus-dominant (63%) or non-Lactobacillus-dominant (25%). Fluctuations in the epithelial barrier protein RPTN between the ovulatory and luteal phase were amplified in women with Gardnerella vaginalis and anaerobic bacteria and reduced when Lactobacillus was dominant.
CONCLUSION: This small study demonstrates that sex hormones modulate neutrophil/leukocyte inflammation, barrier function, and antimicrobial pathways in the female genital tract with the strongest changes occurring during ovulation. The data further suggest a microbiome context for hormone-driven changes in vaginal immunity which may have implications for HIV susceptibility.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HIVzzm321990; female genital tract; menstrual cycle; microbiome; sex hormones; vaginal inflammation

Mesh:

Substances:

Year:  2018        PMID: 29709092     DOI: 10.1111/aji.12863

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  17 in total

1.  A High-throughput Bead-based Affinity Assay Enables Analysis of Genital Protein Signatures in Women At Risk of HIV Infection.

Authors:  Anna Månberg; Frideborg Bradley; Ulrika Qundos; Brandon L Guthrie; Kenzie Birse; Laura Noël-Romas; Cecilia Lindskog; Rose Bosire; James Kiarie; Carey Farquhar; Adam D Burgener; Peter Nilsson; Kristina Broliden
Journal:  Mol Cell Proteomics       Date:  2018-11-30       Impact factor: 5.911

2.  Cooperative Interactions between Trichomonas vaginalis and Associated Bacteria Enhance Paracellular Permeability of the Cervicovaginal Epithelium by Dysregulating Tight Junctions.

Authors:  Annabel S Hinderfeld; Niha Phukan; Ann-Katrein Bär; Anthony M Roberton; Augusto Simoes-Barbosa
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

3.  Matrix Metalloproteinases Expressed in Response to Bacterial Vaginosis Disrupt the Endocervical Epithelium, Increasing Transmigration of HIV.

Authors:  Michelle D Cherne; Amy L Cole; Lisa Newberry; Mary Schmidt-Owens; Michael Deichen; Alexander M Cole
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

4.  Associations Between Dysmenorrhea Symptom-Based Phenotypes and Vaginal Microbiome: A Pilot Study.

Authors:  Chen X Chen; Janet S Carpenter; Xiang Gao; Evelyn Toh; Qunfeng Dong; David E Nelson; Caroline Mitchell; J Dennis Fortenberry
Journal:  Nurs Res       Date:  2021 Jul-Aug 01       Impact factor: 2.381

5.  Mucosal Immunity and HIV Acquisition in Women.

Authors:  Laura Moreno de Lara; Ragav S Parthasarathy; Marta Rodriguez-Garcia
Journal:  Curr Opin Physiol       Date:  2020-08-18

Review 6.  HIV Pathogenesis in the Human Female Reproductive Tract.

Authors:  Marta Rodriguez-Garcia; Kaleigh Connors; Mimi Ghosh
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-15       Impact factor: 5.495

Review 7.  Menstruation: science and society.

Authors:  Hilary O D Critchley; Elnur Babayev; Serdar E Bulun; Sandy Clark; Iolanda Garcia-Grau; Peter K Gregersen; Aoife Kilcoyne; Ji-Yong Julie Kim; Missy Lavender; Erica E Marsh; Kristen A Matteson; Jacqueline A Maybin; Christine N Metz; Inmaculada Moreno; Kami Silk; Marni Sommer; Carlos Simon; Ridhi Tariyal; Hugh S Taylor; Günter P Wagner; Linda G Griffith
Journal:  Am J Obstet Gynecol       Date:  2020-07-21       Impact factor: 10.693

Review 8.  The Interplay Between Reproductive Tract Microbiota and Immunological System in Human Reproduction.

Authors:  Salwan Al-Nasiry; Elena Ambrosino; Melissa Schlaepfer; Servaas A Morré; Lotte Wieten; Jan Willem Voncken; Marialuigia Spinelli; Martin Mueller; Boris W Kramer
Journal:  Front Immunol       Date:  2020-03-16       Impact factor: 7.561

9.  The neovaginal microbiome of transgender women post-gender reassignment surgery.

Authors:  Kenzie D Birse; Kateryna Kratzer; Christina Farr Zuend; Sarah Mutch; Laura Noël-Romas; Alana Lamont; Max Abou; Emilia Jalil; Valdiléa Veloso; Beatriz Grinsztejn; Ruth Khalili Friedman; Kristina Broliden; Frideborg Bradley; Vanessa Poliquin; Fan Li; Carolyn Yanavich; Adam Burgener; Grace Aldrovandi
Journal:  Microbiome       Date:  2020-05-05       Impact factor: 14.650

10.  Dietary α-Linolenic Acid-Rich Flaxseed Oil Exerts Beneficial Effects on Polycystic Ovary Syndrome Through Sex Steroid Hormones-Microbiota-Inflammation Axis in Rats.

Authors:  Ting Wang; Liping Sha; Yiwei Li; Lili Zhu; Zhen Wang; Ke Li; Haixia Lu; Ting Bao; Li Guo; Xiaoxia Zhang; Hao Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.